You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,981,021


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,981,021
Title:Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
Abstract: Provided herein are compositions containing a lysosomal storage disorder replacement enzyme (LSDRE) and a dispersing agent for subcutaneous injection for treatment of lysosomal storage diseases. Kits and methods of treatment are also provided.
Inventor(s): Cao; Mingju (Pomona, CA), Cao; Alexander M. (Pomona, CA)
Assignee: KINETIQ, INC. (Claremont, CA)
Application Number:15/093,613
Patent Claims:1. A composition administered via subcutaneous or intradermal delivery to treat Fabry disease, the composition comprising: alpha-galactosidase A (GLA) in an amount between about 1 mg to about 5 mg; and hyaluronidase in an amount corresponding to about 10 U to about 300 U per single unit dose for facilitating subcutaneous or intradermal delivery of the GLA into a patient in need thereof, wherein the amount of hyaluronidase is limited to ensure that the GLA is delivered throughout the patient's body not including the patient's brain or bone, wherein the GLA is used to treat Fabry disease.

2. The composition of claim 1, wherein the stable formulation is aqueous and is stable for at least 3 months when stored at 2-8.degree. C.

3. The composition of claim 1, wherein the stable formulation is lyophilized and is stable for at least 6 months when stored at 2-8.degree. C.

4. The composition of claim 1, wherein the GLA maintains at least 50% of its activity during storage.

5. The composition of claim 1, wherein the GLA is a mammalian GLA.

6. The composition of claim 1 wherein the GLA is recombinant.

7. The composition of claim 1, wherein the hyaluronidase is in an amount corresponding to 50-100 U per single unit dose.

8. The composition of claim 1, wherein the hyaluronidase is animal-derived.

9. The composition of claim 1, wherein the hyaluronidase is recombinant.

10. The composition of claim 1, wherein the composition is packaged in a prefilled syringe.

11. The composition of claim 10, wherein syringe comprises a first chamber and a second chamber, wherein the first chamber comprises a lyophilized form of the composition, and the second chamber comprises a pharmaceutically acceptable diluent for reconstitution of the composition.

12. The composition of claim 1, wherein the composition is a multi-dose formulation.

13. The composition of claim 1, wherein the hyaluronidase is in an amount corresponding to 10-100 U per single unit dose.

14. The composition of claim 1, wherein the hyaluronidase is in an amount corresponding to 10-200 U-per single unit dose.

15. The composition of claim 1, wherein the hyaluronidase is bovine hyaluronidase.

16. The composition of claim 1, wherein the composition is formulated to give a t.sub.max of the GLA in a patient's bloodstream within 12 hours following administration of a single dose subcutaneous injection of the composition.

17. The composition of claim 1, further comprising an excipient selected from the group consisting of a buffering agent, a non-ionic surfactant, a stabilizer, a preservative and combinations thereof.

18. The composition of claim 17, wherein the buffering agent is selected from the group consisting of phosphate, histidine, citrate and combinations thereof.

19. The composition of claim 17, wherein the stabilizer is selected from the group consisting of mannitol, methionine, glycine, argeinine, albumin, trehalose, sucrose and combinations thereof.

20. The composition of claim 17, wherein the non-ionic surfactant is selected from the group consisting of polysorbate 20, polysorbate 80, poloxamer 188, polyethylene-polypropylene copolymer and combinations thereof, and wherein the stabilizer is selected from the group consisting of mannitol, methionine, glycine, argeinine, albumin, trehalose, sucrose and combinations thereof.

Details for Patent 9,981,021

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 05/05/2004 ⤷  Try a Trial 2035-04-09
Bausch & Lomb Incorporated VITRASE hyaluronidase Injection 021640 12/02/2004 ⤷  Try a Trial 2035-04-09
Amphastar Pharmaceuticals, Inc. AMPHADASE hyaluronidase Injection 021665 10/26/2004 ⤷  Try a Trial 2035-04-09
Akorn, Inc. HYDASE hyaluronidase Injection 021716 10/25/2005 ⤷  Try a Trial 2035-04-09
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.